B Cell Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major B cell chronic lymphocytic leukemia markets are expected to exhibit a CAGR of 4.62% during 2024-2034.
The B cell chronic lymphocytic leukemia market has been comprehensively analyzed in IMARC's new report titled "B Cell Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". B cell chronic lymphocytic leukemia (B-CLL) is a type of cancer that primarily affects B cells, which form white blood cells in the body. It is characterized by the presence of mature-appearing lymphocytes that are larger than normal. As a result, the white blood cells do not function properly and accumulate in the blood, lymph nodes, and other tissues. The symptoms of B-CLL can vary from person to person, and a few patients may not experience any indications in the early stages of the ailment. This disease commonly manifests as fatigue, enlarged lymph nodes, recurrent infections, unintentional weight loss, night sweats, easy bruising or bleeding, etc. The diagnosis of the condition involves a combination of clinical evaluation, medical history assessment, and laboratory tests. A complete blood count and peripheral blood smear are also utilized in patients to determine the appearance and characteristics of the blood cells, including the lymphocytes. Numerous imaging studies, like computed tomography (CT) scans and ultrasounds, may be performed to assess the extent of lymph node enlargement, organ involvement, and staging of the disease.
The increasing cases of genetic mutations that can affect the normal functioning of B lymphocytes, thereby leading to uncontrolled growth and accumulation of abnormal cells, are primarily driving the B cell chronic lymphocytic leukemia market. In addition to this, the growing geriatric population, who are more susceptible to the development of cancer due to a weakened immune response, is also creating a positive outlook for the market. Moreover, the widespread adoption of Bruton's tyrosine kinase inhibitors, such as ibrutinib and acalabrutinib, which block specific proteins responsible for the survival and proliferation of unhealthy cells, is further bolstering the market growth. Apart from this, the escalating application of immunophenotyping technique, since it helps in monitoring the response to regimens and detecting the presence of a small number of leukemia cells that remain after treatment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of chimeric antigen receptor T-cell (CAR-T) therapy, which modifies a patient's own immune cells to recognize and attack tumors, is expected to drive the B cell chronic lymphocytic leukemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the B cell chronic lymphocytic leukemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for B cell chronic lymphocytic leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the B cell chronic lymphocytic leukemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the B cell chronic lymphocytic leukemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the B cell chronic lymphocytic leukemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current B cell chronic lymphocytic leukemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the B cell chronic lymphocytic leukemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the B cell chronic lymphocytic leukemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the B cell chronic lymphocytic leukemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of B cell chronic lymphocytic leukemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of B cell chronic lymphocytic leukemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of B cell chronic lymphocytic leukemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with B cell chronic lymphocytic leukemia across the seven major markets?
What is the size of the B cell chronic lymphocytic leukemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of B cell chronic lymphocytic leukemia?
What will be the growth rate of patients across the seven major markets?
B Cell Chronic Lymphocytic Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for B cell chronic lymphocytic leukemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the B cell chronic lymphocytic leukemia market?
What are the key regulatory events related to the B cell chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by status related to the B cell chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by phase related to the B cell chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by route of administration related to the B cell chronic lymphocytic leukemia market?
The B cell chronic lymphocytic leukemia market has been comprehensively analyzed in IMARC's new report titled "B Cell Chronic Lymphocytic Leukemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". B cell chronic lymphocytic leukemia (B-CLL) is a type of cancer that primarily affects B cells, which form white blood cells in the body. It is characterized by the presence of mature-appearing lymphocytes that are larger than normal. As a result, the white blood cells do not function properly and accumulate in the blood, lymph nodes, and other tissues. The symptoms of B-CLL can vary from person to person, and a few patients may not experience any indications in the early stages of the ailment. This disease commonly manifests as fatigue, enlarged lymph nodes, recurrent infections, unintentional weight loss, night sweats, easy bruising or bleeding, etc. The diagnosis of the condition involves a combination of clinical evaluation, medical history assessment, and laboratory tests. A complete blood count and peripheral blood smear are also utilized in patients to determine the appearance and characteristics of the blood cells, including the lymphocytes. Numerous imaging studies, like computed tomography (CT) scans and ultrasounds, may be performed to assess the extent of lymph node enlargement, organ involvement, and staging of the disease.
The increasing cases of genetic mutations that can affect the normal functioning of B lymphocytes, thereby leading to uncontrolled growth and accumulation of abnormal cells, are primarily driving the B cell chronic lymphocytic leukemia market. In addition to this, the growing geriatric population, who are more susceptible to the development of cancer due to a weakened immune response, is also creating a positive outlook for the market. Moreover, the widespread adoption of Bruton's tyrosine kinase inhibitors, such as ibrutinib and acalabrutinib, which block specific proteins responsible for the survival and proliferation of unhealthy cells, is further bolstering the market growth. Apart from this, the escalating application of immunophenotyping technique, since it helps in monitoring the response to regimens and detecting the presence of a small number of leukemia cells that remain after treatment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of chimeric antigen receptor T-cell (CAR-T) therapy, which modifies a patient's own immune cells to recognize and attack tumors, is expected to drive the B cell chronic lymphocytic leukemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the B cell chronic lymphocytic leukemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for B cell chronic lymphocytic leukemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the B cell chronic lymphocytic leukemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the B cell chronic lymphocytic leukemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the B cell chronic lymphocytic leukemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current B cell chronic lymphocytic leukemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the B cell chronic lymphocytic leukemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the B cell chronic lymphocytic leukemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the B cell chronic lymphocytic leukemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of B cell chronic lymphocytic leukemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of B cell chronic lymphocytic leukemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of B cell chronic lymphocytic leukemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with B cell chronic lymphocytic leukemia across the seven major markets?
What is the size of the B cell chronic lymphocytic leukemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of B cell chronic lymphocytic leukemia?
What will be the growth rate of patients across the seven major markets?
B Cell Chronic Lymphocytic Leukemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for B cell chronic lymphocytic leukemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the B cell chronic lymphocytic leukemia market?
What are the key regulatory events related to the B cell chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by status related to the B cell chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by phase related to the B cell chronic lymphocytic leukemia market?
What is the structure of clinical trial landscape by route of administration related to the B cell chronic lymphocytic leukemia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - UNMET NEEDS
10 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - KEY ENDPOINTS OF TREATMENT
11 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - MARKETED PRODUCTS
11.1 List of B Cell Chronic Lymphocytic Leukemia Marketed Drugs Across the Top 7 Markets
11.1.1 Treanda (Bendamustine) - Astellas Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Venclexta (Venetoclax) - AbbVie/Genentech
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Gazyva (Obinutuzumab) - Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Arzerra (Ofatumumab) - Genmab/Novartis
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Zydelig (Idelalisib) - Gilead Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - PIPELINE DRUGS
12.1 List of B Cell Chronic Lymphocytic Leukemia Pipeline Drugs Across the Top 7 Markets
12.1.1 NVG111 - NovalGen
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Epcoritamab - Genmab/AbbVie
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 IOV 2001 - Iovance Biotherapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Pirtobrutinib - Loxo Oncology
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SC291 - Sana Biotechnology
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. B CELL CHRONIC LYMPHOCYTIC LEUKEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
16 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - UNMET NEEDS
10 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - KEY ENDPOINTS OF TREATMENT
11 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - MARKETED PRODUCTS
11.1 List of B Cell Chronic Lymphocytic Leukemia Marketed Drugs Across the Top 7 Markets
11.1.1 Treanda (Bendamustine) - Astellas Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Venclexta (Venetoclax) - AbbVie/Genentech
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Gazyva (Obinutuzumab) - Roche
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Arzerra (Ofatumumab) - Genmab/Novartis
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Zydelig (Idelalisib) - Gilead Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - PIPELINE DRUGS
12.1 List of B Cell Chronic Lymphocytic Leukemia Pipeline Drugs Across the Top 7 Markets
12.1.1 NVG111 - NovalGen
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Epcoritamab - Genmab/AbbVie
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 IOV 2001 - Iovance Biotherapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Pirtobrutinib - Loxo Oncology
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 SC291 - Sana Biotechnology
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. B CELL CHRONIC LYMPHOCYTIC LEUKEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 B Cell Chronic Lymphocytic Leukemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 B Cell Chronic Lymphocytic Leukemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 B Cell Chronic Lymphocytic Leukemia - Access and Reimbursement Overview
16 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 B CELL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
